Comparative Serological Assays for the Study of H5 and H7 Avian Influenza Viruses
Author(s) -
Eleonora Molesti,
Adelaide Milani,
Calogero Terregino,
Giovanni Cattoli,
Nigel Temperton
Publication year - 2013
Publication title -
influenza research and treatment
Language(s) - English
Resource type - Journals
eISSN - 2090-1399
pISSN - 2090-1380
DOI - 10.1155/2013/286158
Subject(s) - influenza a virus subtype h5n1 , virology , antigenic drift , vaccination , serology , biology , virus , h5n1 genetic structure , outbreak , pandemic , antigenic shift , antigen , flock , highly pathogenic , influenza a virus , antibody , medicine , immunology , covid-19 , disease , paleontology , pathology , infectious disease (medical specialty)
The nature of influenza virus to randomly mutate and evolve into new types is an important challenge in the control of influenza infection. It is necessary to monitor virus evolution for a better understanding of the pandemic risk posed by certain variants as evidenced by the highly pathogenic avian influenza (HPAI) viruses. This has been clearly recognized in Egypt following the notification of the first HPAI H5N1 outbreak. The continuous circulation of the virus and the mass vaccination programme undertaken in poultry have resulted in a progressive genetic evolution and a significant antigenic drift near the major antigenic sites. In order to establish if vaccination is sufficient to provide significant intra- and interclade cross-protection, lentiviral pseudotypes derived from H5N1 HPAI viruses (A/Vietnam/1194/04, A/chicken/Egypt-1709-01/2007) and an antigenic drift variant (A/chicken/Egypt-1709-06-2008) were constructed and used in pseudotype-based neutralization assays (pp-NT). pp-NT data obtained was confirmed and correlated with HI and MN assays. A panel of pseudotypes belonging to influenza Groups 1 and 2, with a combination of reporter systems, was also employed for testing avian sera in order to support further application of pp-NT as an alternative valid assay that can improve avian vaccination efficacy testing, vaccine virus selection, and the reliability of reference sera.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom